LEADER 02526nam  2200589 a 450 
001 9910969216603321
005 20200520144314.0
010   $a9781608052974
010   $a1608052974
035   $a(CKB)2670000000148694
035   $a(EBL)864207
035   $a(OCoLC)779141401
035   $a(SSID)ssj0000942934
035   $a(PQKBManifestationID)11492225
035   $a(PQKBTitleCode)TC0000942934
035   $a(PQKBWorkID)10976890
035   $a(PQKB)11670260
035   $a(OCoLC)785783102
035   $a(MiAaPQ)EBC864207
035   $a(DE-B1597)731336
035   $a(DE-B1597)9781608052974
035   $a(EXLCZ)992670000000148694
100   $a20120315d2012      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aMultiple myeloma $ea new era of treatment strategies /$feditors, Klaus Podar, Kenneth C. Anderson
205   $a1st ed.
210   $a[U.S.A.] $cBentham Science Publishers$d[2012]
215   $a1 online resource (217 p.)
300   $aDescription based upon print version of record.
311 08$a9781608056095 
311 08$a1608056090 
320   $aIncludes bibliographical references and index.
327   $asection 1. Multiple myeloma -- section 2. Treatment guidelines -- section 3. The bone marrow microenvironment and the pathogenesis of multiple myeloma -- section 4. New treatment strategies.
330   $aMultiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced disruption of the bone marrow homeostasis between the highly organized cellular and extracellular compartments supports MM cell proliferation, survival, migration, and drug resistance via activation of various signaling pathways. Based on this knowledge, the prototypic drugs thalidomide, bortezomib, and lenalidomide, which target both MM cell
606   $aMultiple myeloma$xTreatment
615  0$aMultiple myeloma$xTreatment.
676   $a616.99/418
676   $a616.99418
700   $aPodar$b Klaus, $4aut$4http://id.loc.gov/vocabulary/relators/aut$01800395
701   $aPodar$b Klaus$01800395
701   $aAnderson$b Kenneth C$0876632
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910969216603321
996   $aMultiple myeloma$94345157
997   $aUNINA

LEADER 01841nas  2200589-a 450 
001 9910895979903321
005 20260127110032.0
035   $a(DE-599)ZDB2571984-1
035   $a(CKB)110978978553039
035   $a(CONSER)---78645947-
035   $a(DE-599)2571984-1
035   $a(EXLCZ)99110978978553039
100   $a20780316b19741988  ---         -
101 0 $aeng
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aSurvey Sarajevo
210   $aSarajevo $cUniversity of Sarajevo
215   $a1 online resource
311 08$aPrint version: Survey Sarajevo. 0350-0144 (DLC)   78645947 (OCoLC)3722903 
330   $a"Periodical for social studies."
517 1 $aPregled international series
517 3 $aSurvey
531   $aSURVEY SARAJEVO PERIODICAL FOR SOCIAL STUDIES
606   $aSocial sciences$vPeriodicals
606   $aSocial conditions$2fast$3(OCoLC)fst01919811
606   $aSocial sciences$2fast$3(OCoLC)fst01122877
606   $aSocial sciences$vPeriodicals$2nli
606   $aSOCIALISM$2unbist
606   $aCULTURAL DEVELOPMENT$2unbist
606   $aYUGOSLAVIA$2unbist
607   $aYugoslavia$xSocial conditions$vPeriodicals
607   $aYugoslavia$2fast
607   $a4.800$2gtt
607   $aYugoslavia$xSocial conditions$vPeriodicals$2nli
608   $aPeriodicals.$2fast
608   $aPeriodicals.$2lcgft
615  0$aSocial sciences
615  7$aSocial conditions.
615  7$aSocial sciences.
615  7$aSocial sciences
615  7$aSOCIALISM.
615  7$aCULTURAL DEVELOPMENT.
615  7$aYUGOSLAVIA.
676   $a300/.5
712 02$aUniverzitet u Sarajevu.
906   $aJOURNAL
912   $a9910895979903321
920   $aexl_impl conversion
996   $aSurvey Sarajevo$94232221
997   $aUNINA